Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Net Cash Flow (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Net Cash Flow for 15 consecutive years, with -$24000.0 as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 112.37% to -$24000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$323000.0 through Dec 2025, down 59.11% year-over-year, with the annual reading at -$325000.0 for FY2025, 60.1% down from the prior year.
  • Net Cash Flow hit -$24000.0 in Q4 2025 for Guided Therapeutics, up from -$96000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $2.2 million in Q3 2022 to a low of -$627000.0 in Q3 2023.
  • Historically, Net Cash Flow has averaged -$5150.0 across 5 years, with a median of -$143000.0 in 2023.
  • Biggest five-year swings in Net Cash Flow: soared 690.03% in 2022 and later tumbled 680.49% in 2023.
  • Year by year, Net Cash Flow stood at $102000.0 in 2021, then plummeted by 476.47% to -$384000.0 in 2022, then skyrocketed by 63.54% to -$140000.0 in 2023, then skyrocketed by 238.57% to $194000.0 in 2024, then tumbled by 112.37% to -$24000.0 in 2025.
  • Business Quant data shows Net Cash Flow for GTHP at -$24000.0 in Q4 2025, -$96000.0 in Q3 2025, and $70000.0 in Q2 2025.